Call Options

11 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.49 - $7.2 $1.43 Million - $2.29 Million
-318,300 Reduced 69.91%
137,000 $811,000
Q2 2024

Aug 15, 2024

BUY
$4.33 - $6.79 $1.65 Million - $2.59 Million
381,800 Added 519.46%
455,300 $2.23 Million
Q1 2024

May 07, 2024

BUY
$4.03 - $7.81 $221,247 - $428,769
54,900 Added 295.16%
73,500 $526,000
Q4 2023

Feb 14, 2024

SELL
$1.63 - $4.63 $81,011 - $230,111
-49,700 Reduced 72.77%
18,600 $84,000
Q3 2023

Nov 14, 2023

SELL
$2.13 - $3.84 $78,171 - $140,928
-36,700 Reduced 34.95%
68,300 $161,000
Q2 2023

Aug 11, 2023

SELL
$2.1 - $6.37 $108,780 - $329,966
-51,800 Reduced 33.04%
105,000 $369,000
Q1 2023

May 16, 2023

SELL
$3.74 - $7.46 $1.05 Million - $2.09 Million
-280,200 Reduced 64.12%
156,800 $603,000
Q4 2022

Feb 14, 2023

BUY
$4.56 - $6.61 $233,927 - $339,093
51,300 Added 13.3%
437,000 $2.26 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $6.63 $547,500 - $967,980
146,000 Added 60.91%
385,700 $2.38 Million
Q2 2022

Aug 15, 2022

BUY
$2.11 - $4.06 $469,897 - $904,161
222,700 Added 1310.0%
239,700 $904,000
Q1 2022

May 16, 2022

BUY
$2.73 - $11.94 $46,410 - $202,980
17,000 New
17,000 $46,000

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $251M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.